GlassScriptPhysician profile
Edward F Boylan
NPI 1144286105
$4,367.64
in general payments reported to CMS, 2019-2025
19 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $392 · 2021: $437 · 2022: $596 · 2023: $570 · 2024: $730 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,646.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,540.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $553.77 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $540.60 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $500.92 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $367.43 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Intuitive Surgical, INC. | $128.75 | 2025 | |
| Medtronic, INC. | $109.69 | 2023 | Interstim |
| Glaxosmithkline, LLC. | $99.00 | 2023-2025 | Shingrix, Trelegy Ellipta |
| Vivus LLC | $96.75 | 2022-2024 | Qsymia |
| Amgen INC. | $96.44 | 2024-2025 | Repatha, Otezla, Otezla |
| Allergan, INC. | $85.61 | 2019-2020 | |
| Abbvie INC. | $63.45 | 2021-2024 | Linzess, Viberzi, Creon |
| Pfizer INC. | $54.38 | 2025 | |
| Astellas Pharma US INC | $40.14 | 2025 | Veozah |
| Ardelyx, INC. | $23.01 | 2025 | Ibsrela |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $18.31 | 2024 | Xyosted |
| Electromed, INC. | $17.81 | 2024 | Smartvest |
| Axsome Therapeutics, INC. | $16.00 | 2025 | Symbravo |
| Boston Scientific Corporation | $15.04 | 2025 | Ams 700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Boylan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.